Figure 7

Ibandronate diminishes MAPK activation in NE-treated SHR-VSMCs. Cells were pretreated for 24 h with Iban (10 μM), and then stimulated with 0.1 μM NE for 5 min. Figure shows a representative Western blot of phospho-p38 (p-p38), phospho-ERK (p-ERK1/2) and phospho-JNK (p-JNK1/2/3) and p38, ERK and JNK (used as controls). Figures show data as mean±s.e.m. of 3 experiments. The ratio of p-ERK1/2or p-p38 or p-JNK1/2/3 is set to ‘1’ for SHR control group. *P<0.05 vs control. #P<0.05 vs NE.